Last reviewed: July 14, 2026 Last updated: July 14, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
F., Bergman, B., Liu, B., Cui, X., & Brown, K
Blue Shield of California formulary and drug coverage policies California Medi-Cal dropped GLP-1 obesity coverage effective January 1, 2026, joining several other states that reduced coverage amid rising drug costs
Interventions for vitiligo
This is still within the normal range
Participants were randomized to placebo or one of four Retatrutide dose groups (1mg, 4mg, 8mg, or 12mg weekly)